David A. Siegel Onconova Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Onconova Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 73,066 shares of ONTX stock, worth $43,108. This represents 0.0% of its overall portfolio holdings.

Number of Shares

73,066

Previous 77,966 6.28%

Holding current value

$43,108

Previous $58,000 25.86%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.67 - $1.01 $3,283 - $4,949	-4,900 Reduced 6.28%	73,066 $73,000
Q4 2023 Feb 14, 2024	SELL	$0.62 - $0.79 $10,461 - $13,329	-16,873 Reduced 17.79%	77,966 $58,000
Q3 2023 Nov 14, 2023	SELL	$0.71 - $1.15 $34,435 - $55,774	-48,500 Reduced 33.84%	94,839 $67,000
Q2 2023 Aug 14, 2023	BUY	$0.67 - $1.42 $78,122 - $165,572	116,600 Added 436.07%	143,339 $169,000
Q1 2023 May 15, 2023	SELL	$0.69 - $1.42 $16,145 - $33,228	-23,400 Reduced 46.67%	26,739 $19,000

Q4 2022 Feb 14, 2023	SELL	$0.63 - $0.97 $47,880 - $73,720	-76,000 Reduced 60.25%	50,139 $32,000
Q3 2022 Nov 14, 2022	SELL	$0.95 - $1.45 $50,134 - $76,520	-52,773 Reduced 29.5%	126,139 $111,000
Q2 2022 Aug 15, 2022	SELL	$1.04 - $1.9 $180,336 - $329,460	-173,400 Reduced 49.22%	178,912 $236,000
Q1 2022 May 16, 2022	BUY	$1.46 - $2.82 $83,220 - $160,740	57,000 Added 19.3%	352,312 $648,000
Q4 2021 Feb 14, 2022	BUY	$2.49 - $3.73 $735,326 - $1.1 Million	295,312 New	295,312 $753,000
Q3 2021 Nov 15, 2021	SELL	$3.81 - $6.76 $59,561 - $105,679	-15,633 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$6.28 - $16.2 $98,175 - $253,254	15,633 New	15,633 $108,000

Others Institutions Holding ONTX

# of Institutions

Shares Held

1.71M

Call Options Held

2.6K

Put Options Held

View Full List

About Onconova Therapeutics, Inc.

Ticker ONTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,895,600
Market Cap $12.3M
Description
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent...

More about ONTX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account